Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence of myeloid neoplasms in Spain (2002-2013), a population-based study of the Spanish network of cancer registries

  • Solans, Marta|||0000-0002-2397-0435
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Ameijide, Alberto
  • Merino, Susana
  • Rojas, Dolores
  • Alemán, Araceli
  • Banqueri, Emilia
  • Chico, Matilde
  • Marcos, Ana Isabel
  • de Castro, Visitación
  • Gil, Leire
  • López de Munain, Arantza|||0000-0001-6820-9124
  • Puigdemont, Montse|||0000-0001-9961-3699
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Perucha, Josefina
  • Ruiz-Armengol, Patricia
  • Chirlaque López, María Dolores
  • Guevara, Marcela|||0000-0001-9242-6364
  • Carulla, Marià
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002-2013 using harmonized data from 13 population-based cancer registries. Cases (n = 17,522) were grouped following the HAEMACARE groupings and 2013-European standardized incidence rates (ASR), incidence trends, and estimates for 2021 were calculated. ASR per 100,000 inhabitants was 5.14 (95% CI: 5.00-5.27) for myeloproliferative neoplasms (MPN), 4.71 (95% CI: 4.59-4.84) for myelodysplastic syndromes (MDS), 3.91 (95% CI: 3.79-4.02) for acute myeloid leukemia, 0.83 (95% CI: 0.78-0.88) for MDS/MPN, 0.35 (95% CI: 0.32-0.39) for acute leukemia of ambiguous lineage, and 0.58 (95% CI: 0.53-0.62) for not-otherwise specified (NOS) cases. This study highlights some useful points for public health authorities, such as the remarkable variability in incidence rates among Spanish provinces, the increasing incidence of MPN, MDS, and MDS/MPN during the period of study, in contrast to a drop in NOS cases, and the number of cases expected in 2021 based on these data (8446 new MNs).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differences in the impact of covid-19 on pathology laboratories and cancer diagnosis in girona

  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Puigdemont, Montse|||0000-0001-9961-3699
  • Rubió-Casadevall, Jordi
  • Vidal Vila, Anna
  • López-Bonet, Eugeni
  • Martín-Romero, Ferran
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
Introduction: The recent COVID-19 pandemic has compromised socio-health care, with consequences for the diagnosis and follow-up of other pathologies. The aim of this study was to evaluate the impact of COVID-19 on cancer diagnosis in Girona, Spain. Methodology: Observational study of samples received in two pathology laboratories during 2019-2020 (tertiary hospital in Girona and county hospital in Figueres). Date, sample type, and location and morphology were available. Samples were recoded to determine malignancy and grouped by location. Comparisons were made by calendar year and period of exposure to COVID-19. Results: 102,360 samples were included: 80,517 from Girona and 21,843 from Figueres. The reduction in activity in the pathology laboratories in 2020 compared to the previous year was 25.4% in Girona and 27.5% in Figueres. The reduction in cancer diagnoses in 2020 compared to 2019 was 6.8% in Girona and 21% in Figueres. In both laboratories, a decrease was observed in the diagnoses of neoplasms of the lip, oral cavity and pharynx, larynx, colon, rectum and anus, kidney and urinary system, melanoma, and central nervous system. A statistically significant higher probability of a sample received in the pathology laboratory displaying malignancy during COVID-19 was found (Girona: OR = 1.28, 95% CI: 1.23-1.34; Figueres: OR = 1.10, 95% CI: 1.01-1.20) with respect to the COVID-19-free period. Conclusions: The COVID-19 pandemic has resulted in a reduction in cancer diagnoses by pathology departments that varies according to tumor location and type of hospital. Despite this, the optimization of care resources and the recovery effort have partially reduced the impact of the pandemic in certain neoplasms.